1. Home
  2. SBI vs ANIX Comparison

SBI vs ANIX Comparison

Compare SBI & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Western Asset Intermediate Muni Fund Inc

SBI

Western Asset Intermediate Muni Fund Inc

N/A

Current Price

$7.01

Market Cap

108.9M

Sector

Finance

ML Signal

N/A

Logo Anixa Biosciences Inc.

ANIX

Anixa Biosciences Inc.

N/A

Current Price

$2.77

Market Cap

114.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SBI
ANIX
Founded
1992
1982
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
108.9M
114.0M
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
SBI
ANIX
Price
$7.01
$2.77
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
★ $9.75
AVG Volume (30 Days)
59.6K
★ 333.6K
Earning Date
01-01-0001
09-09-2026
Dividend Yield
★ 4.52%
N/A
EPS Growth
N/A
★ 12.82
EPS
★ N/A
N/A
Revenue
N/A
★ $210,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.88
$2.32
52 Week High
$8.01
$5.46

Technical Indicators

Market Signals
Indicator
SBI
ANIX
Relative Strength Index (RSI) 27.54 48.33
Support Level N/A $2.82
Resistance Level $7.93 $3.03
Average True Range (ATR) 0.10 0.13
MACD -0.02 0.04
Stochastic Oscillator 22.33 93.51

Price Performance

Historical Comparison
SBI
ANIX

About SBI Western Asset Intermediate Muni Fund Inc

Western Asset Intermediate Muni Fd Inc is a diversified closed-end management investment company. The fund's objective is to provide a high level of current income exempt from Federal income taxes. Under normal market conditions, the Fund will invest at least 80% of its total assets in municipal obligations. In addition, under normal market conditions, the Fund will invest at least 80% of its total assets in debt securities that are, at the time of investment, rated investment grade by a nationally recognized statistical rating organization or, if unrated, of equivalent quality as determined by the investment manager.

About ANIX Anixa Biosciences Inc.

Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.

Share on Social Networks: